Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 297 clinical trials
featured
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

  • 244 views
  • 23 Nov, 2020
  • 5 locations
featured
CTOT14

CTOT14

  • 70 views
  • 08 Nov, 2020
  • 1 location
Study of Efficacy Safety Tolerability Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody CFZ533 in Liver Transplant Recipients With Additional 12-month Follow-up

The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 dose regimens in liver transplant recipients.

  • 0 views
  • 13 Jul, 2021
  • 42 locations
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver

  • 0 views
  • 27 Jan, 2021
  • 11 locations
Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients

The main objective of the study is to evaluate the impact of the Personalized Pharmaceutical Plan on the therapeutic adherence to immunosuppressive treatments one year after liver or kidney transplantation.

  • 0 views
  • 26 Feb, 2021
  • 12 locations
CPAP in Liver Transplant

ventilation in patients who develop acute hypoxemia after liver transplant. Hypoxemia complicates the recovery of 30-50 % of patients after abdominal surgery; endotracheal intubation and mechanical

  • 4 views
  • 07 Nov, 2020
  • 1 location
Dexmedetomidine and Liver Transplantation

1.1. Background 1.1.1. Perioperative ischaemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction, graft loss, and mortality.

  • 0 views
  • 23 Jan, 2021
  • 1 location
MSC Therapy in Liver Transplantation

The general aim of the present study is to test a cell therapy with third-party allogeneic ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients. MSCs will be

  • 19 views
  • 22 Jan, 2021
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation

The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day delay of cyclosporine in combination with MMF.

liver transplant
immunosuppression
everolimus
cyclosporine
  • 12 views
  • 08 Nov, 2020
  • 1 location